You are here: Industry Insights > Mesoblast

News List

Novartis terminates remestemcel-L development agreement with Mesoblast Pharmaceutical-Technology
December 16, 2021
Novartis has cancelled an agreement to develop, produce and market Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L.
Mesoblast’s remestemcel-L lowers mortality in Covid-19 ARDS patients pharmaceutical-technology
May 06, 2021
Mesoblast has reported that results from a trial showed remestemcel-L reduced mortality in ventilator-dependent Covid-19 patients aged below 65 years with moderate/severe acute respiratory distress syndrome (ARDS) through day 60 by 46%.
Mesoblast signs ARDS therapy development deal with Novartis pharmaceutical-technology
November 25, 2020
Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of the former’s mesenchymal stromal cell (MSC) product remestemcel-L.
Novartis secures rights to Mesoblast’s remestemcel-L for ARDS pharmatimes
November 23, 2020
Swiss pharma Novartis has inked an exclusive licence and collaboration agreement with Mesoblast to develop remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS.
Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs firstwordpharma
January 15, 2019
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit facility with Hercules Capital, Inc.
Deals this week: Mesoblast, Orexigen Therapeutics Ireland, Savior Lifetec Corporation pharmaceutical-technology
March 31, 2017
Mesoblast has raised A$52.5m ($40m) from a fully underwritten private placement of shares to its existing global ...